Proxalutamide is a Small Molecule owned by Kintor Pharmaceutical, and is involved in 19 clinical trials, of which 9 were completed, 9 are ongoing, and 1 is planned.

Proxalutamide (GT-0918) acts by decreasing the androgenic activity. It inhibits androgen binding with AR's ligand binding domain and decreases the expression of AR, effectively lowering the expression of the proteins ACE2 and TMPRSS2. Thus, proxalutamide prevents the coronavirus from infecting normal host cells prevents viral replication and reproduction. In addition, proxalutamide also promotes the clearance of pathogens and decreases inflammation by activating the Nrf2 pathway, which activates several antioxidative genes and proteins and reduces the intensity of the cytokine response. The inhibition of androgen receptor activity result in the mechanism which may delay prostate cancer progression. The drug also decreases the growth of cancer cells and induces cancer cell death.

The revenue for Proxalutamide is expected to reach a total of $949m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Proxalutamide NPV Report.

Proxalutamide is originated and owned by Kintor Pharmaceutical.

Proxalutamide Overview

Proxalutamide (GT-0918) is under development for the treatment of Coronavirus COVID-19 disease, hormone senstive, castration resistant prostate cancer (CRPC) and AR positive metastatic breast cancer, HER-2 negative breast cancer and triple negative breast cancer. It is administered through oral and formulated in the form of tablet. The drug candidate acts by targeting androgen receptor.

Kintor Pharmaceutical Overview

Kintor Pharmaceutical (Kintor) is a clinical stage drug company. It is involved in discovering and developing novel small molecule therapeutics targeting cancer and other androgen receptor related diseases. The company’s lead product candidate Proxalutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Destorsertib (GT0486), GT-1798F, GT20029 and others. It offers therapeutic drugs for various disease such as metastatic castration-resistant prostate cancer, hepatocellular carcinoma, gastric carcinoma, urothelial carcinoma, Leukaemia and other disease. Kintor is involved in discovering medicine and drugs for novel diseases such as COVID -19, prostate, breast, blood and liver cancers. In addition it also carries out research and development operations to discover treatment for alopecia and acne. It carters to clients across Taiwan, Hong Kong, the Us, Brazil, and China. The company runs its operations across Hong Kong, China, and the US. Kintor is headquartered in Suzhou, Jiangsu, China.

The company reported revenues of (Renminbi) CNY34.2 million for the fiscal year ended December 2021 (FY2021). The operating loss of the company was CNY839.6 million in FY2021, compared to an operating loss of CNY504.9 million in FY2020. The net loss of the company was CNY842.1 million in FY2021, compared to a net loss of CNY508.3 million in FY2020.

Quick View – Proxalutamide

Report Segments
  • Innovator
Drug Name
  • Proxalutamide
Administration Pathway
  • Oral
Therapeutic Areas
  • Infectious Disease
  • Oncology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.